Rasburicase: Future directions in tumor lysis management

Expert Opinion on Biological Therapy

Volumn 8, Issue 10, 2008, Pages 1595-1604

  Hochberg, Jessica ^a   Cairo, Mitchell S ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Rasburicase; Tumor lysis

Indexed keywords

ALLOPURINOL; ANTINEOPLASTIC AGENT; CALCIUM; INFUSION FLUID; PHOSPHOROUS ACID; POTASSIUM; RASBURICASE; RITUXIMAB; URIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ALKALINIZATION; AREA UNDER THE CURVE; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; HEMATOLOGIC MALIGNANCY; HEMODIALYSIS; HUMAN; HYDRATION; HYPERURICEMIA; KIDNEY FAILURE; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER TOXICITY; METHEMOGLOBINEMIA; MYALGIA; NAUSEA; PRURITUS; RECOMMENDED DRUG DOSE; RIGOR; SIDE EFFECT; TUMOR LYSIS SYNDROME; URIC ACID BLOOD LEVEL; URTICARIA; VOMITING; WHEEZING;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; TUMOR LYSIS SYNDROME; URATE OXIDASE;

EID: 54349128384     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.8.10.1595     Document Type: Article

References (25)

1. Alavi S, Arzanian MT, Abbasian MR, Ashena Z. Tumor lysis syndrome in children with non-Hodgkin lymphoma. Pediatr Hematol Oncol 2006;23(1):65-70
2. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004;127(1):3-11
3. Del Toro G, Morris E, Cairo MS. Tumor lysis syndrome: pathophysiology, definition, and alternative treatment approaches. Clin Adv Hematol Oncol 2005;3(1):54-61
4. Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med 1993;94(2):133-9
5. Hochberg J, Cairo MS. Tumor lysis syndrome: current perspective. Haematologica 2008;93(1):9-13
6. Jeha S. Tumor lysis syndrome. Semin Hematol 2001;38(4 Suppl 10):4-8
7. Yarpuzlu AA. A review of clinical and laboratory findings and treatment of tumor lysis syndrome. Clin Chim Acta 2003;333(1):13-8
8. Howard SC, Pui CH. Pitfalls in predicting tumor lysis syndrome. Leuk Lymphoma 2006;47(5):782-5
9. Bessmertny O, Robitaille LM, Cairo MS. Rasburicase: a new approach for preventing and/or treating tumor lysis syndrome. Curt Pharm Des 2005;11(32):4177-85
10. Klinenberg JR, Goldfinger SE, Seegmiller JE. The effectiveness of the xanthine oxidase inhibitor allopurinol in the treatment of gout. Ann Intern Med 1965;62:639-47
11. Yeldandi AV, Yeldandi V, Kumar S, et al. Molecular evolution of the urate oxidase-encoding gene in hominoid primates: nonsense mutations. Gene 1991;109(2):281-4
12. Legoux R, Delpech B, Dumont X, et al. Cloning and expression in escherichia coli of the gene encoding aspergillus flavus urate oxidase. J Biol Chem 1992;267(12):8565-70
13. Masera G, Jankovic M, Zurlo MG, et al. Urate-oxidase prophylaxis of uric acid-induced renal damage in childhood leukemia. J Pediatr 1982;100(1):152-5
14. Pui CH, Relling MV, Lascombes F, et al. Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia 1997;11(11):1813-6
15. Pui CH, Mahmoud HH, Wiley JM, et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 2001; 19(3):697-704
16. Coiffier B, Mounier N, Bologna S, et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study. J Clin Oncol 2003;21(23):4402-6
17. Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001;97(10):2998-3003
18. Pui CH, Jeha S, Irwin D, Camitta B. Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia 2001;15(10):1505-9
19. Bosly A, Sonet A, Pinkerton CR, et al. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer 2003;98(5):1048-54
20. Jeha S, Kantarjian H, Irwin D, et al. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia 2005;19(1):34-8
21. Navolanic PM, Pui CH, Larson RA, et al. Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002. Leukemia 2003;(3):499-514
22. Cairo MS, Gerrard M, Sposto R, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 2007;109(7):2736-43
23. Candrilli S, Bell T, Irish W, et al. A comparison of inpatient length of stay and costs among patients with hematologic malignancies (excluding hodgkin disease) associated with and without acute renal failure. Clin Lymphoma Myeloma 2008;8(1):44-51
24. Annemans L, Moeremans K, Lamotte M, et al. Incidence, medical resource utilization and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin's lymphoma in four European countries. Leuk Lymphoma 2003;44(1):77-83
25. Coiffier B, Altman A, Pui CH, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008;26(16):2767-78